AMLX - Amylyx Pharmaceuticals Class Action: Johnson Fistel Encourages Amylyx Investors to Seek Counsel Before Lead Plaintiff Class Action Deadline | Benzinga
SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX). The class action is on behalf of shareholders who purchased or otherwise acquired securities between November 11, 2022 to November 8, 2023, both dates inclusive (the "Class Period"). Investors are hereby notified that they have until April 9, 2024, to move the Court to serve as lead plaintiff in this action.
The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) defendants had overstated RELYVRIO's (a dual UPRBax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol, for the treatment of ALS in adults in the ...